Evaluation of Negative Symptoms and Cognitive Function After Administration of Antipsychotics in Healthy Volunteer
NCT ID: NCT01185418
Last Updated: 2010-08-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
80 participants
OBSERVATIONAL
2009-03-31
2009-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Aripiprazole Augmentation for Clozapine-Treated Patients With Refractory Schizophrenia
NCT00328367
Amisulpride in Schizophrenic Patients
NCT00331981
A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With Dementia
NCT00249145
A Randomized Double-blind Trial With 6 Antipsychotic Drugs for Schizophrenia
NCT02192723
A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol and Placebo in Patients With Chronic Schizophrenia
NCT00249132
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
risperidone
risperidone
aripiprazole
aripiprazole
haloperidol
haloperidol
amisulpride
amisulpride
lactose
lactose
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
risperidone
aripiprazole
haloperidol
amisulpride
lactose
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* 2\) anyone who has progressive disease or in unstable medical condition unfit for the trial,
* 3\) anyone who has been diagnosed in psychiatric terms in the past, depends on psychotropic substance, or has overdosed or depended on the substance or alcohol (except for coffee or tobacco) within 1 month from the trial start,
* 4\) anyone who is suicidal or highly probable of suicides, or
* 5\) anyone who has test results considered clinically meaningful
18 Years
38 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chonbuk National University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Chonbuk National University Hospital, Jeonju, Korea
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chonbuk national university hospital
Jeonju, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CBIRB0226-22
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.